SCHEMBL4773426

SCHEMBL4773426

CC(C)(C)OC(=O)NCc1ccc(NS(=O)(=O)CCc2cccc(Cl)c2Cl)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAMPT P43490 2/20 0.43
GAA P10253 1/20 0.40
CA1 P00915 2/20 0.39
CA2 P00918 1/20 0.39
REN P00797 1/20 0.38
DRD2 P14416 1/20 0.38
POLB P06746 1/20 0.38
MAPK1 P28482 1/20 0.38
ATM Q13315 1/20 0.38
NQO2 P16083 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
CA12 O43570 1/20 0.38
CA7 P43166 1/20 0.38
CA14 Q9ULX7 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
MAPT P10636 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
MEN1 O00255 1/20 0.37
LMNA P02545 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4769626 0.85 SMN1; SMN2 (0.41) GAACA1CA2POLBATM
SCHEMBL4791414 0.85 DRD2 (0.48) GAACA1CA2DRD2MAPK1
SCHEMBL4773551 0.84 PPARA (0.45) POLBL3MBTL1SMN1; SMN2NPSR1MEN1
SCHEMBL4767898 0.84 DRD2 (0.43) GAACA1CA2DRD2NQO2
SCHEMBL4775215 0.84 DRD2 (0.45) CA1CA2DRD2NQO2L3MBTL1
SCHEMBL4776450 0.83 STAT3 (0.44) CA1CA2CA12CA14SMN1; SMN2
SCHEMBL4767847 0.83 DRD2 (0.47) CA1CA2DRD2MAPK1NQO2
SCHEMBL4777500 0.80 EPHX2 (0.45) POLBL3MBTL1SMN1; SMN2NPSR1MAPT
SCHEMBL4770596 0.79 PTPRB (0.44) MAPTMEN1LMNAKMT2A
SCHEMBL4773543 0.79 EPHX2 (0.42) L3MBTL1SMN1; SMN2NPSR1MAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1942888-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2008-07-16 EP claimed
US-20070135435-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INCORPORATED 2007-06-14 US claimed
WO-2007056078-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2007-05-18 WO claimed
EP-1942888-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2008-07-16 EP disclosed
US-20070135435-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INCORPORATED 2007-06-14 US disclosed
WO-2007056078-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2007-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135435-A1 Certain chemical entities, compositions, and methods KIF5B, KIF2C, PLK1 NAMPT 3369/4885GAA 466/4885CA1 3116/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.